{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(11)"],"submitter":["Fasching PA"],"pubmed_abstract":["<h4>Importance</h4>Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) has demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/ERBB2 (formerly HER2)-negative early breast cancer. Evaluating the efficacy and safety of adjuvant ribociclib beyond the planned 3-year treatment period is critical for understanding the long-term impact on recurrences.<h4>Objective</h4>To evaluate efficacy and safety of adjuvant ribociclib in an exploratory 4-year analysis of the NATALEE (New Adjuvant Trial With Ribociclib [LEE011]) randomized clinical trial, with all patients no longer receiving ribociclib treatment.<h4>Design, setting, and participants</h4>This exploratory analysis of an international, open-label,"],"journal":["JAMA oncology"],"pagination":["1364-1372"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12464853"],"repository":["biostudies-literature"],"pubmed_title":["Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial."],"pmcid":["PMC12464853"],"pubmed_authors":["Zarate JP","Hortobagyi GN","Stroyakovskiy D","Yardley DA","Hurvitz SA","Fasching PA","Fresco R","Bardia A","Moroose R","Chia S","Barrios C","Huang CS","Li Z","Visco F","Xu B","Waters S","Slamon DJ","Untch M","Martin M","Loi S","Crown J","Im SA"],"additional_accession":[]},"is_claimable":false,"name":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.","description":"<h4>Importance</h4>Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) has demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/ERBB2 (formerly HER2)-negative early breast cancer. Evaluating the efficacy and safety of adjuvant ribociclib beyond the planned 3-year treatment period is critical for understanding the long-term impact on recurrences.<h4>Objective</h4>To evaluate efficacy and safety of adjuvant ribociclib in an exploratory 4-year analysis of the NATALEE (New Adjuvant Trial With Ribociclib [LEE011]) randomized clinical trial, with all patients no longer receiving ribociclib treatment.<h4>Design, setting, and participants</h4>This exploratory analysis of an international, open-label,","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-07-15T06:51:54.59Z","creation":"2026-06-30T03:28:50.472Z"},"accession":"S-EPMC12464853","cross_references":{"pubmed":["40996773"],"doi":["10.1001/jamaoncol.2025.3700"]}}